17th Annual BIO CEO & Investor Conference to Feature Congressional Leaders, Institutional Investors, Industry Analysts and Senior Biotechnology ExecutivesJan 22 2015
BIO CEO Program to highlight latest in clinical development, timely policy perspectives and industry outlook for 2015
|
|
17th Annual BIO CEO & Investor Conference to Feature U.S. Representatives Fred Upton and Diana DeGetteJan 8 2015
Reps. Upton and DeGette will discuss 21st Century Cures Initiative to help expedite cures and treatments
|
|
BIO Urges FDA to Release Guidance on BiosimilarsJan 7 2015
Biosimilars raise novel and complex questions of science and law that require updated legal and regulatory frameworks
|
|
BIO Applauds U.S.-China Agreement on Steps to Enhance Ag Biotech TradeDec 19 2014
The Biotechnology Industry Organization (BIO) applauds the United States and Chinese governments for a successful 2014 U.S.-China Joint Commission on Commerce and Trade (JCCT).
|
|
More Than 150 Companies Expected to Present at the 17th Annual BIO CEO & Investor ConferenceDec 15 2014
Companies to share their stories with top public and venture capital investors
|
|
EPA Must Improve Administration of the Renewable Fuel Standard, Not Seek Legislative Change to It, BIO SaysDec 10 2014
The Environmental Protection Agency’s (EPA) delays in administering the Renewable Fuel Standard (RFS) generate uncertainty for the advanced biofuel industry and undercut investment, BIO said today in reaction to the House Oversight and Government Reform Subcommittee on Energy Policy, Health Care & Entitlements’ hearing on the agency’s administration of the program.
|
|
BIO: Secretary Burwell’s PREP Act Declaration Will Advance Ebola Vaccine DevelopmentDec 9 2014
Washington, D.C. (December 9, 2014) – The Biotechnology Industry Organization (BIO) applauds today’s declaration by Health and Human Services Secretary Sylvia M. Burwell under the Public Readiness and Emergency Preparedness (PREP) Act which will help advance the development and availability of experimental Ebola vaccines. The declaration provides immunity under U.S. law against legal claims related to the manufacturing, testing, development, distribution and administration of three experimental Ebola vaccines.
|
|
17th Annual BIO CEO & Investor Conference to Highlight Industry Financing, Current Policy Trends and the 2015 Market OutlookDec 8 2014
... |
|
BIO Applauds House Passage of Ebola Treatments Bill, Urges Swift Action by President Obama to Sign into LawDec 5 2014
BIO applauds the unanimous House passage late Wednesday of the Adding Ebola to the FDA Priority Review Voucher Program Act. The Act would add Ebola to the Food and Drug Administration’s (FDA) tropical disease priority review voucher program, under which developers of a vaccine or treatment for a qualifying tropical disease receive a voucher for FDA priority review for another product of its choice.
|
|
BIO: Blue Ribbon Study Panel on Biodefense Will Provide Crucial Guidance to Strengthen Preparedness against Devastating ThreatsDec 4 2014
Washington, D.C. (December 4, 2014) – Today marks the inaugural meeting of the Blue Ribbon Study Panel on Biodefense, a bipartisan panel co-chaired by former Senator Joe Lieberman and former Governor and Homeland Security Secretary Tom Ridge. Panelists former Senator Tom Daschle, former Secretary of Health and Human Services Donna Shalala, former US Homeland Security Advisor Kenneth Wainstein, and Biotechnology Industry Organization (BIO) President and CEO and former Representative Jim Greenwood. The study will be directed by Dr. Robert Kadlec, former special assistant to the President for homeland security and senior director for biological defense policy in the White House Homeland Security Council.
|
